Tenders/Pancreatic Cancer Detection Consortium: Research Units (U01 Clinical Trial Optional)

Pancreatic Cancer Detection Consortium: Research Units (U01 Clinical Trial Optional)

National Institutes of Health
Published: Sep 25, 2026
Updated: Sep 26, 2026
Source: grants_gov

About This Opportunity

This is a grants contract in the health and medical services and Research sectors, with a focus on Data Science. Located in United States, North America, this opportunity is open to firms and consortiums.

Published through Grants.gov, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for grants in the health and medical services sector. Grant applications generally require a detailed project proposal, a clear results framework, and evidence of the applicant's capacity to deliver the proposed activities. Interested parties should review the full documentation on the original source before submitting their proposal.

Description

Through this Notice of Funding Opportunity (NOFO), NCI solicits applications for the Research Units (RUs), one of the two scientific components of the Pancreatic Cancer Detection Consortium (PCDC), to conduct research on early detection of pancreatic ductal adenocarcinoma (PDAC) and characterization of its precursor lesions to identify patients who are at high risk of progression to cancer. The PCDC will continue to address one of the four research priorities identified in the NCI's 2014 Scientific Framework for Pancreatic Ductal Adenocarcinoma (PDAC). The PCDC will support research for the development and testing of new molecular and imaging biomarkers for detecting PDAC early and for identifying patients at high risk of PDAC (because of genetic factors, family history and/or the presence of precursor lesions) who could be candidates for early intervention. The PCDC-RUs will consist of multi-disciplinary teams and will undertake studies to: identify and test biomarkers measurable in bodily fluids for early detection of PDAC and/or its precursor lesions; develop molecular- and/or imaging-based markers of pancreatic cysts and determine which lesions are likely to progress to cancer; develop molecular- and/or imaging-based approaches for screening populations at high risk of PDAC; use machine learning and computational approaches towards biomarker discovery and/or validation; and conduct biomarker validation studies. The PCDC-RUs will also collect longitudinal biospecimens for building a biorepository. Each PCDC-RU is expected to participate in collaborative activities with other PCDC-RUs and share ideas, biospecimens, and data within the Consortium. Agency: National Institutes of Health CFDA: 93.393 Eligible Applicants: Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are not allowed. Applicant Types: Native American tribal organizations (other than Federally recognized tribal governments); State governments; Public housing authorities/Indian housing authorities; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Private institutions of higher education; County governments; For profit organizations other than small businesses; Independent school districts; Native American tribal governments (Federally recognized); Special district governments; Public and State controlled institutions of higher education; City or township governments; Others (see text field entitled "Additional Information on Eligibility" for clarification); Small businesses Cost Sharing: No Contact: National Institutes of Health Email: ncipcdc@nih.gov

Data provenance

This notice is sourced from Grants.gov and was originally published on September 25, 2026. Last refreshed today. BidsFactory mirrors official procurement notices and links back to the source for full legal text.

About National Institutes of Health

National Institutes of Health has issued 115 procurement notices on BidsFactory, including 95 currently open and 0 awarded contracts. Activity concentrates in Health & Medical, Research & Innovation, and Information & Communication Technology. All notices are published for United States. Notices are distributed via Grants.gov. Most recent publication: September 25, 2026.

Frequently asked questions about this tender

Who is the contracting authority?

This notice was issued by National Institutes of Health in United States. The authority is responsible for evaluating bids, awarding the contract, and managing performance.

What type of contract is this?

This is a Grants contract in the Health & Medical sector. The classification helps bidders match the opportunity to their qualifications and registered scope of supply.

Where will the contract be performed?

The contract is for delivery in United States. Foreign bidders should review local registration, taxation, and any in-country presence requirements before submitting.

How can I submit a bid?

Visit Grants.gov to access the full notice, required documents, and submission instructions provided by the contracting authority.

Find tenders like this automatically

Set up alerts and filters that match your business — never miss a relevant opportunity again.

See plans

Key Details

Contract Type
Grants
Eligibility
Firms / Consortiums
Language
English

Source

grants_gov
grants_gov
Official Source

Contracting Authority

National Institutes of Health
🇺🇸United States

Matching Experts

Are you a consultant?

Join our Expert Network and get matched with relevant tenders.